G207 engineered herpes simplex virus: Phase I

MDG published in Gene Therapy that G207 was well tolerated in a U.S./U.K. Phase I trial in 21 patients with recurrent, progressive malignant glioma who were radiation- and chemotherapy experienced. Th...